IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

Lonza Signs Manufacturing Agreement with U.S. Biopharma Firm

10:06 AM MDT | May 29, 2009 | DEEPTI RAMESH

Lonza says it has entered into a manufacturing services agreement with biopharmaceutical firm Morphotek (Exton, PA), to support the development and manufacturing of a subset of antibodies in Morphotek’s therapeutics pipeline. Lonza will reserve capacity for commercial manufacturing of Morphotek’s lead compound farletuzumab, which recently entered Phase III clinical trials for ovarian cancer, under the deal. Sijbesma: Strength in life sciences units. Morphotek, a subsidiary of pharma company Eisai (Woodcliff Lake, NJ), specializes in the development of...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.



Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.

 














 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa